Form 4: Ultragenyx CFO Howard Horn Reports Stock and Option Awards

Chief Financial Officer Howard Horn reports acquisition of stock and option awards in Ultragenyx Pharmaceutical Inc.

Summary

• Howard Horn, CFO of Ultragenyx Pharmaceutical Inc., reported transactions involving the company's stock and options on March 1, 2025.
• Horn acquired 15,653 shares of common stock through Restricted Stock Units (RSUs) and was granted options to purchase 28,160 shares.
• The RSUs vest in equal installments over four years from the grant date.
• The stock options vest 1/4th on the first anniversary of the grant date, and then 1/48th monthly thereafter.
• Following these transactions, Horn beneficially owns 107,954 shares of common stock and options for 28,160 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The document reflects standard executive compensation practices, which are generally viewed as a positive sign of alignment between management and shareholders.

Positives

• The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedules encourage long-term commitment and performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules of the RSUs and stock options suggest an expectation of continued service and contribution from the CFO.

Industry Context

This type of filing is standard for publicly traded companies and reflects compensation practices for key executives. Stock options and RSUs are common tools used to incentivize and retain talent in the pharmaceutical industry.

Comparison to Industry Standards

• Equity compensation is a standard practice among publicly traded pharmaceutical companies.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also utilize stock options and RSUs as part of their executive compensation packages.
• The vesting schedules and grant sizes are generally aligned with industry norms for companies of similar size and stage of development.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of management's commitment to the company's long-term success.
• Employees may see the grants as a reflection of the company's investment in its leadership.

Key Dates